Patents by Inventor Takao Isogai
Takao Isogai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180068760Abstract: In a compound type conductive wire structure 1, a plurality of wire-stranded portions 3 are provided to constitute main wire-twisted portions 5 embedded in an insulator matrix 2. Each of the wire-stranded portions 3 has a subsidiary wire-stranded portion 4 to serve as a diameter-reduced wire-twisted portion 8. Such is the structure that it enables to provide a flexibility, pliability and high strength with a diameter-increased wire-twisted portion 10, while securing a friction-resistant, vibration-resistant, impact-resistant and yet excellent bending capability. It is possible to prevent the main wire-twisted portions 5 from coming loose when removing a plastic layer coated over the main wire-twisted portion 5. The core wire 9 has a curved surface 9a which partly engages in surface-to-surface contact with the diameter-reduced wire-twisted portion 8. This makes it possible to evenly disperse stresses applied to the curved surface 9a of the core wire 9.Type: ApplicationFiled: August 17, 2017Publication date: March 8, 2018Applicant: G.S. Electech Inc.Inventors: Shingo Okuda, Yoshihiro Sato, Takao Isogai
-
Publication number: 20130095107Abstract: The invention provides a novel polypeptide and a specific partial peptide thereof, as well as a novel polynucleotide and a specific partial nucleotide thereof, that can be used as a biomarker specific for the brain/nerves or specific for nerve differentiation; an expression vector for such a polynucleotide and a specific partial peptide thereof; a transformant incorporating such an expression vector; an antisense molecule, RNAi-inducing nucleic acid (e.g., siRNA), aptamer, or antibody for such a biomarker, and a composition comprising the same; a mammalian cell or non-human mammal wherein the expression or a function of such a biomarker is regulated; a measuring means (e.g., primer set, nucleic acid probe, antibody, aptamer) for such a biomarker, and a reagent comprising the same and the like.Type: ApplicationFiled: December 13, 2011Publication date: April 18, 2013Inventors: Ai WAKAMATSU, Junichi YAMAMOTO, Takao ISOGAI
-
Patent number: 8309687Abstract: It is an object of the present invention to provide diagnostic reagents, pharmaceuticals and the like for particular diseases, and providing means that are useful in developing such reagents, pharmaceuticals and the like. The present invention provides a novel polypeptide and a specific partial peptide thereof, as well as a novel polynucleotide and a specific partial nucleotide thereof, that can be used as cancer-specific biomarkers; an expression vector for such a polynucleotide and a specific partial peptide thereof; a transformant incorporating such an expression vector; an antisense molecule, RNAi-inducing nucleic acid (e.g., siRNA), aptamer, or antibody for a cancer-specific biomarker, and a composition comprising the same; a mammalian cell or non-human mammal wherein the expression or a function of a cancer-specific biomarker is regulated; a measuring means (e.g., primer set, nucleic acid probe, antibody, aptamer) for a cancer-specific biomarker, and a reagent comprising them and the like.Type: GrantFiled: March 13, 2008Date of Patent: November 13, 2012Assignee: Reverse Proteomics Research Institute Co., Ltd.Inventors: Ai Wakamatsu, Junichi Yamamoto, Takao Isogai
-
Patent number: 8153764Abstract: The invention provides a polypeptide and a specific partial peptide thereof, as well as a polynucleotide and a specific partial nucleotide thereof, that can be used as a biomarker specific for the brain/nerves or specific for nerve differentiation; an expression vector for such a polynucleotide and a specific partial peptide thereof; a transformant incorporating such an expression vector; an antisense molecule, RNAi-inducing nucleic acid (e.g., siRNA), aptamer, or antibody for such a biomarker, and a composition comprising the same; a mammalian cell or non-human mammal wherein the expression or a function of such a biomarker is regulated; a measuring means (e.g., primer set, nucleic acid probe, antibody, aptamer) for such a biomarker, and a reagent comprising the same and the like.Type: GrantFiled: March 13, 2008Date of Patent: April 10, 2012Assignee: Reverse Proteomics Research Institute Co., Ltd.Inventors: Ai Wakamatsu, Junichi Yamamoto, Takao Isogai
-
Patent number: 8110662Abstract: A cDNA fragment participating in the maintenance of smooth muscle differentiation was isolated using a culture system of chicken gizzard smooth muscle cells, the differential display method and the subtracted hybridization method. Using the obtained cDNA sequence as a query, cDNA sequences of Helix Research Institute (Japanese Patent Application No. 2000-118776) were retrieved, and thus, a novel gene “C-NT2RP3001495” was obtained. The protein encoded by this gene has two WW domains that participate in protein interactions in the N-terminal domain. Evidence suggests that this protein binds to other proteins, and thus regulates the intracellular signal transduction, gene expression, and so on, thereby participating in the maintenance of the differentiation of smooth muscle cells. This protein and compounds regulating the expression thereof are markedly useful in developing drugs for various diseases associated with abnormality in the maintenance of smooth muscle cell differentiation.Type: GrantFiled: October 9, 2007Date of Patent: February 7, 2012Assignees: Chugai Seiyaku Kabushiki KaishaInventors: Toshio Ota, Takao Isogai, Tetsuo Nishikawa, Koji Hayashi, Kaoru Otsuka, Jun-Ichi Yamamoto, Shizuko Ishii, Tomoyasu Sugiyama, Ai Wakamatsu, Keiichi Nagai, Tetsuji Otsuki, Shin-Ichi Funahashi, Shoji Miyata, Kenji Sobue, Kenichiro Hayashi
-
Publication number: 20110269141Abstract: The problems of the present invention are to provide target proteins and target genes for bioactive substances such as drugs, and means that enable the development of novel bioactive substances using the same. The present invention provides target proteins and target genes for bioactive substances; screening methods for substances capable of regulating bioactivities; bioactivity regulators; a bioactive substance derivative production method; a complex comprising a bioactive substance and a target protein, and a method of producing the complex; and kits comprising a bioactive substance or a salt thereof; determination methods for the onset or risk of onset of a specified disease or condition, determination methods for susceptibility to a bioactive substance, and determination kits used for the determination methods, and the like.Type: ApplicationFiled: February 20, 2008Publication date: November 3, 2011Applicant: REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD.Inventors: Katsuhisa Murayama, Tadakazu Yamauchi, Kouichi Tsuchiya, Kazuo Komiya, Morikazu Kito, Yuko Isono, Noriyuki Inomata, Yorimasa Suwa, Ai Wakamatsu, Junichi Yamamoto, Takao Isogai
-
Publication number: 20100100979Abstract: It is an object of the present invention to provide diagnostic reagents, pharmaceuticals and the like for particular diseases, and providing means that are useful in developing such reagents, pharmaceuticals and the like. The present invention provides a novel polypeptide and a specific partial peptide thereof, as well as a novel polynucleotide and a specific partial nucleotide thereof, that can be used as cancer-specific biomarkers; an expression vector for such a polynucleotide and a specific partial peptide thereof; a transformant incorporating such an expression vector; an antisense molecule, RNAi-inducing nucleic acid (e.g., siRNA), aptamer, or antibody for a cancer-specific biomarker, and a composition comprising the same; a mammalian cell or non-human mammal wherein the expression or a function of a cancer-specific biomarker is regulated; a measuring means (e.g., primer set, nucleic acid probe, antibody, aptamer) for a cancer-specific biomarker, and a reagent comprising them and the like.Type: ApplicationFiled: March 13, 2008Publication date: April 22, 2010Applicant: REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD.Inventors: Ai Wakamatsu, Junichi Yamamoto, Takao Isogai
-
Publication number: 20100098695Abstract: The invention provides a polypeptide and a specific partial peptide thereof, as well as a polynucleotide and a specific partial nucleotide thereof, that can be used as a biomarker specific for the brain/nerves or specific for nerve differentiation; an expression vector for such a polynucleotide and a specific partial peptide thereof; a transformant incorporating such an expression vector; an antisense molecule, RNAi-inducing nucleic acid (e.g., siRNA), aptamer, or antibody for such a biomarker, and a composition comprising the same; a mammalian cell or non-human mammal wherein the expression or a function of such a biomarker is regulated; a measuring means (e.g., primer set, nucleic acid probe, antibody, aptamer) for such a biomarker, and a reagent comprising the same and the like.Type: ApplicationFiled: March 13, 2008Publication date: April 22, 2010Applicant: REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD.Inventors: Ai Wakamatsu, Junichi Yamamoto, Takao Isogai
-
Publication number: 20090311748Abstract: Novel full-length cDNAs are provided. cDNA derived from human have been isolated. The full-length nucleotide sequences of the cDNA and amino acid sequences encoded by the nucleotide sequences have been determined. Because the cDNA of the present invention are full-length and contain the translation start site, they provide information useful for analyzing the functions of the polypeptide.Type: ApplicationFiled: July 13, 2009Publication date: December 17, 2009Applicant: Acceleron Pharma Inc.Inventors: Takao Isogai, Tomoyasu Sugiyama, Tetsuji Otsuki, Ai Wakamatsu, Hiroyuki Sato, Shizuko Ishii, Jun-ichi Yamamoto, Yuuko Isono, Yuri Hio, Kaoru Otsuka, Keiichi Nagai, Ryotaro Irie, Ichiro Tamechika, Naohiko Seki, Tsutomu Yoshikawa, Motoyuki Otsuka, Kenji Nagahari, Yasuhiko Masuho
-
Patent number: 7560541Abstract: Novel full-length cDNAs are provided. cDNA derived from human have been isolated. The full-length nucleotide sequences of the cDNA and amino acid sequences encoded by the nucleotide sequences have been determined. Because the cDNA of the present invention are full-length and contain the translation start site, they provide information useful for analyzing the functions of the polypeptide.Type: GrantFiled: June 25, 2007Date of Patent: July 14, 2009Assignee: Acceleron Pharma, Inc.Inventors: Takao Isogai, Tomoyasu Sugiyama, Tetsuji Otsuki, Ai Wakamatsu, Hiroyuki Sato, Shizuko Ishii, Jun-ichi Yamamoto, Yuuko Isono, Yuri Hio, Kaoru Otsuka, Keiichi Nagai, Ryotaro Irie, Ichiro Tamechika, Naohiko Seki, Tsutomu Yoshikawa, Motoyuki Otsuka, Kenji Nagahari, Yasuhiko Masuho
-
Publication number: 20090156413Abstract: Disclosed in this invention are methods, systems, databases, user-interfaces, software, media, and services useful for evaluating interactions between chemical compounds and proteins and for utilizing the information resulting from such evaluation for the purpose of discovering chemical compounds for medical and other fields. An approach termed “reverse proteomics” is disclosed. This invention generates an enormously large pool of new target proteins for drug discovery, novel methods for designing of new drugs, and a previously unthinkable pool of virtually synthesized small molecules for therapeutic uses. This invention is also applicable, for example, to discovery of substitutes for environmentally hazardous chemicals, more effective agrochemicals, and healthier food additives.Type: ApplicationFiled: February 10, 2009Publication date: June 18, 2009Inventors: Renpei Nagashima, Takao Isogai, Noriaki Hirayama
-
Publication number: 20080171353Abstract: The clone PLACE6002312 having a structure characteristic of G protein-coupled receptor was isolated from a human placental full-length cDNA library prepared by the oligo-capping method. Database search revealed that PLACE6002312 had the highest homology to HISTAMINE H2 RECEPTOR. Analysis for the expression of PLACE6002312 gene in human tissues revealed that the gene was expressed in various tissues, such as heart, liver, and ovary. In addition, histamine was found to be one of ligands for PLACE 6002312 by ligand-binding assay. Furthermore, a full-length cDNA for the mouse homolog of PLACE6002312 was isolated and the deduced amino acid sequence was revealed to comprise a structure characteristic of G protein-coupled receptor. PLACE6002312 can be used to screen for agonists and antagonists useful as pharmaceuticals and to diagnose various diseases caused by the abnormal activity or expression of the polypeptide.Type: ApplicationFiled: August 7, 2007Publication date: July 17, 2008Applicant: Astellas Pharma Inc.Inventors: Tomoyasu SUGIYAMA, Noriyuki Morikawa, Ai Wakamatsu, Tamaki Oda, Ryotaro Irie, Takao Isogai, Yasuhiko Masuho
-
Publication number: 20080069826Abstract: A cDNA fragment participating in the maintenance of smooth muscle differentiation was isolated using a culture system of chicken gizzard smooth muscle cells, the differential display method and the subtracted hybridization method. Using the obtained cDNA sequence as a query, cDNA sequences of Helix Research Institute (Japanese Patent Application No. 2000-118776) were retrieved, and thus, a novel gene “C-NT2RP3001495” was obtained. The protein encoded by this gene has two WW domains that participate in protein interactions in the N-terminal domain. Evidence suggests that this protein binds to other proteins, and thus regulates the intracellular signal transduction, gene expression, and so on, thereby participating in the maintenance of the differentiation of smooth muscle cells. This protein and compounds regulating the expression thereof are markedly useful in developing drugs for various diseases associated with abnormality in the maintenance of smooth muscle cell differentiation.Type: ApplicationFiled: October 9, 2007Publication date: March 20, 2008Inventors: Toshio Ota, Takao Isogai, Tetsuo Nishikawa, Koji Hayashi, Kaoru Otsuka, Jun-Ichi Yamamoto, Shizuko Ishii, Tomoyasu Sugiyama, Ai Wakamatsu, Keiichi Nagai, Tetsuji Otsuki, Shin-Ichi Funahashi, Shoji Miyata, Kenji Sobue, Kenichiro Hayashi
-
Publication number: 20080032304Abstract: cDNA derived from human have been isolated. The full-length nucleotide sequences of the cDNA and amino acid sequences encoded by the nucleotide sequences have been determined. Because the cDNA of the present invention are full-length and contain the translation start site, they provide information useful for analyzing the functions of the polypeptide.Type: ApplicationFiled: June 25, 2007Publication date: February 7, 2008Inventors: Takao Isogai, Tomoyasu Sugiyama, Tetsuji Otsuki, Ai Wakamatsu, Hiroyuki Sato, Shizuko Ishii, Jun-ichi Yamamoto, Yuuko Isono, Yuri Hio, Kaoru Otsuka, Keiichi Nagai, Ryotaro Irie, Ichiro Tamechika, Naohiko Seki, Tsutomu Yoshikawa, Motoyuki Otsuka, Kenji Nagahari, Yasuhiko Masuho
-
Patent number: 7279558Abstract: A cDNA fragment participating in the maintenance of smooth muscle differentiation was isolated using a culture system of chicken gizzard smooth muscle cells, the differential display method and the subtracted hybridization method. Using the obtained cDNA sequence as a query, cDNA sequences of Helix Research Institute (Japanese Patent Application No. 2000-118776) were retrieved, and thus, a novel gene “C-NT2RP3001495” was obtained. The protein encoded by this gene has two WW domains that participate in protein interactions in the N-terminal domain. Evidence suggests that this protein binds to other proteins, and thus regulates the intracellular signal transduction, gene expression, and so on, thereby participating in the maintenance of the differentiation of smooth muscle cells. This protein and compounds regulating the expression thereof are markedly useful in developing drugs for various diseases associated with abnormality in the maintenance of smooth muscle cell differentiation.Type: GrantFiled: February 4, 2005Date of Patent: October 9, 2007Assignees: Chugai Seiyaku Kabushiki KaishaInventors: Toshio Ota, Takao Isogai, Tetsuo Nishikawa, Koji Hayashi, Kaoru Otsuka, Jun-Ichi Yamamoto, Shizuko Ishii, Tomoyasu Sugiyama, Ai Wakamatsu, Keiichi Nagai, Tetsuji Otsuki, Shin-Ichi Funahashi, Shoji Miyata, Kenji Sobue, Kenichiro Hayashi
-
Patent number: 7217800Abstract: A cDNA encoding a novel LTC4 receptor has been isolated. Provision of the novel protein, an LTC4 receptor, enabled binding experiments using the LTC4. By screening for compounds that modulate LTC4 receptor activity based on these binding experiments, development of drugs targeting the LTC4 receptor becomes possible.Type: GrantFiled: September 2, 2004Date of Patent: May 15, 2007Assignees: Astellas Pharma Inc., Helix Research InstituteInventors: Jun Takasaki, Masazumi Kamohara, Mitsuyuki Matsumoto, Tetsu Saito, Tohru Sugimoto, Toshio Ota, Takao Isogai, Tetsuo Nishikawa, Yuri Kawai
-
Publication number: 20070105122Abstract: Primers for synthesizing full-length cDNAs and their use are provided. 5602 cDNA encoding a human protein has been isolated and nucleotide sequences of 5?-, and 3?-ends of the cDNA have been determined. Furthermore, primers for synthesizing the full-length cDNA have been provided to clarify the function of the protein encoded by the cDNA. The full-length cDNA of the present invention containing the translation start site provides information useful for analyzing the functions of the protein.Type: ApplicationFiled: August 13, 2004Publication date: May 10, 2007Inventors: Toshio Ota, Takao Isogai, Tetsuo Nishikawa, Koji Hayashi, Kaoru Saito, Junichi Yamamoto, Shizuko Ishii, Tomoyasu Sugiyama, Ai Wakamatsu, Keiichi Nagai, Tetsuji Otsuki
-
Publication number: 20070082345Abstract: Novel human secretory proteins or membrane proteins, and full length cDNAs encoding the proteins are provided. 173 kinds of novel proteins and polynucleotides encoding these proteins have been isolated. The proteins of the present invention are useful as candidates for medicines or as target molecules for developing medicines. The polynucleotides of the present invention are used to produce these proteins.Type: ApplicationFiled: May 8, 2006Publication date: April 12, 2007Inventors: Toshio Ota, Takao Isogai, Tetsuo Nishikawa, Yuri Kawai, Tomoyasu Sugiyama, Koji Hayashi
-
Patent number: 7193069Abstract: Novel full-length cDNAs are provided. 2443 cDNA derived from human have been isolated. The full-length nucleotide sequences of the cDNA and amino acid sequences encoded by the nucleotide sequences have been determined. Because the cDNA of the present invention are full-length and contain the translation start site, they provide information useful for analyzing the functions of the polypeptide.Type: GrantFiled: March 28, 2002Date of Patent: March 20, 2007Assignee: Research Association for BiotechnologyInventors: Takao Isogai, Tomoyasu Sugiyama, Tetsuji Otsuki, Ai Wakamatsu, Hiroyuki Sato, Shizuko Ishii, Jun-ichi Yamamoto, Yuuko Isono, Yuri Hio, Kaoru Otsuka, Keiichi Nagai, Ryotaro Irie, Ichiro Tamechika, Naohiko Seki, Tsutomu Yoshikawa, Motoyuki Otsuka, Kenji Nagahari, Yasuhiko Masuho
-
Publication number: 20070048740Abstract: Novel full-length cDNAs are provided. 1,995 cDNA derived from human have been isolated. The full-length nucleotide sequences of the cDNA and amino acid sequences encoded by the nucleotide sequences have been determined. Because the cDNA of the present invention are full-length and contain the translation start site, they provide information useful for analyzing the functions of the polypeptide.Type: ApplicationFiled: February 13, 2004Publication date: March 1, 2007Inventors: Takao Isogai, Junichi Yamamoto, Tetsuo Nishikawa, Yuko Isono, Tomoyasu Sugiyama, Tetsuji Otsuki, Ai Wakamatsu, Shizuko Ishii, Keiichi Nagai, Ryotaro Irie